Cardiovascular Benefits of Wearing Particulate-Filtering facemasks

Evaluating performance of facemasks in reducing ambient particulate matter (PM10? PM2.5? PM1) exposure and theirs wearing on acute cardiovascular effects: A Randomized crossover trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181214041961N1

Enrollment

Registered

2019-01-14

Start date

2019-01-24

Completion date

Unknown

Last updated

2019-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute cardiovascular effects.

Interventions

Wearing particulate-filtering facemask.

Eligibility

Sex/Gender

Male

Age

20 Years to 30 Years

Inclusion criteria

Inclusion criteria: no history of tobacco smoking (never smokers) no alcohol addiction no clinically diagnosed chronic cardiopulmonary diseases no recent infections

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Heart rate variability. Timepoint: Heart rate variability will be continuously monitored during the 2nd 24 hr in each intervention. Method of measurement: A 12-lead continuous electrographic Holter monitor will be used.;Blood pressure. Timepoint: Blood pressure will be continuously monitored during the 2nd 24 hr in each intervention. Method of measurement: A portable and automated ambulatory BP monitoring and recording instrument will be used.;Biomarkers of NT-proBNP and hs-cTnT. Timepoint: A venous blood sample will be collected at the end of ecah intervention in order to examine the level of each above-mentioned biomarkers. Method of measurement: They will be measured using enzyme-linked immunosorbent assays.	—

Measure

Time frame

Heart rate variability. Timepoint: Heart rate variability will be continuously monitored during the 2nd 24 hr in each intervention. Method of measurement: A 12-lead continuous electrographic Holter monitor will be used.;Blood pressure. Timepoint: Blood pressure will be continuously monitored during the 2nd 24 hr in each intervention. Method of measurement: A portable and automated ambulatory BP monitoring and recording instrument will be used.;Biomarkers of NT-proBNP and hs-cTnT. Timepoint: A venous blood sample will be collected at the end of ecah intervention in order to examine the level of each above-mentioned biomarkers. Method of measurement: They will be measured using enzyme-linked immunosorbent assays.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasih Tajdini

Tehran University of Medical Sciences

Drmasih84@yahoo.com+98 21 6643 7147

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026